Merck’s Sanat Chattopadhyay called for stronger leadership, data-driven oversight, and shared accountability to raise pharmaceutical quality standards. Susan J. Schniepp, Distinguished Fellow, ...

Orexin neuron loss drives narcolepsy type 1’s multisymptom phenotype, and historical management has been symptom-by-symptom rather than deficit-correcting, leaving underlying biology untreated. Orexin ...

FDA authorized mFlusiva for adults 50–65 and ≥65, contingent on an additional confirmatory trial in older adults, with commercial availability targeted for the 2026–2027 flu season. A large outcomes ...

Kent Malmros is senior director of training at Veeva Systems. He has spent the majority of his career delivering technology-enabled training solutions to life-sciences companies and has held ...

OSTP's July 2026 report to Trump diagnoses U.S. science slowdown and pushes deregulation, new funding models, reshoring, and AI-driven "Genesis Mission." Much of the report is broad science policy: ...

PharmTech spoke with Dr. Hui-Yin (Harry) Li, president and CEO of Wilmington PharmaTech, about steps that should be taken to build a productive relationship between sponsor and contract organizations.

AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact. Six months after industry experts laid out their predictions for 2026, many of ...